Abstract
Gene transfer and oncolytic viruses provide new therapeutic approaches for the treatment of hematologic malignancies. However, it is still too early to introduce gene delivery or oncolytic viruses into standard clinical protocol. It is very important to discuss the obstacles that gene transfer and oncolytic virotherapy face for the further clinical application for the treatment of hematologic malignancies, and updating the advances made to overcome them. The major concerns in this review include the approaches of the development of immuno-stimulatory gene transfer mediated-vaccination for leukemia therapy, RNAi-based therapy for leukemia and enhancement of sensitivity of target malignant cells to virotherapy and alteration of host immune response to favor oncolytic viruses. We conclude with a perspective on the future of the gene therapy and virotherapy for the treatment of hematologic malignancies, emphasizing the problems we should solve and the technological requirements for further clinical applications.
Keywords: Gene transfer, vaccination, RNAi, oncolytic viruses, hematologic malignancies.
Current Gene Therapy
Title:Approaches to Optimize Gene Therapy for the Treatment of Hematologic Malignancies: Overcoming the Obstacles
Volume: 16 Issue: 6
Author(s): Yingzhe Jiang, Bing Xia, Yizhuo Zhang*Wen Xu
Affiliation:
- Tianjin Medical University Cancer Institute and Hospital, 1 Huanhuxi Road, Hexi District, Tianjin 300060,China
Keywords: Gene transfer, vaccination, RNAi, oncolytic viruses, hematologic malignancies.
Abstract: Gene transfer and oncolytic viruses provide new therapeutic approaches for the treatment of hematologic malignancies. However, it is still too early to introduce gene delivery or oncolytic viruses into standard clinical protocol. It is very important to discuss the obstacles that gene transfer and oncolytic virotherapy face for the further clinical application for the treatment of hematologic malignancies, and updating the advances made to overcome them. The major concerns in this review include the approaches of the development of immuno-stimulatory gene transfer mediated-vaccination for leukemia therapy, RNAi-based therapy for leukemia and enhancement of sensitivity of target malignant cells to virotherapy and alteration of host immune response to favor oncolytic viruses. We conclude with a perspective on the future of the gene therapy and virotherapy for the treatment of hematologic malignancies, emphasizing the problems we should solve and the technological requirements for further clinical applications.
Export Options
About this article
Cite this article as:
Jiang Yingzhe, Xia Bing, Zhang Yizhuo*, Xu Wen, Approaches to Optimize Gene Therapy for the Treatment of Hematologic Malignancies: Overcoming the Obstacles, Current Gene Therapy 2016; 16 (6) . https://dx.doi.org/10.2174/1566523217666170215154755
DOI https://dx.doi.org/10.2174/1566523217666170215154755 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dendritic Cells in Colorectal Cancer and a Potential for their Use in Therapeutic Approaches
Current Pharmaceutical Design Potentials of Hydrogels in Cancer Therapy
Current Cancer Therapy Reviews Therapeutic Targeting of Malignant Glioma
Anti-Cancer Agents in Medicinal Chemistry Sirtuin Inhibitors: An Overview from Medicinal Chemistry Perspective
Anti-Cancer Agents in Medicinal Chemistry Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML)
Current Drug Targets Recent Advances in Oncological Submissions of Dendrimer
Current Pharmaceutical Design VEGF in the Muscular Layer of Placental Blood Vessels: Immuno- Expression in Preeclampsia and Intrauterine Growth Restrictrion and its Association with the Antioxidant Status
Cardiovascular & Hematological Agents in Medicinal Chemistry p53-Induced Apoptosis and Inhibitors of p53
Current Medicinal Chemistry Stem Cells in Kidney Transplantation: A Review of Chimerism-Based Protocols to Induce Transplantation Tolerance
Current Regenerative Medicine (Discontinued) Interleukin-6 In Rheumatoid Arthritis - From The Laboratory To The Bedside
Current Pharmaceutical Design Recent Patents on Glioblastoma Signaling
Recent Patents on Biomarkers Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Histone Deacetylase Inhibitors: Molecular and Biological Activity as a Premise to Clinical Application
Current Drug Metabolism Novel Drugs Targeting Microtubules: the Role of Epothilones
Current Pharmaceutical Design Chronic Administration of Single Weekly Paclitaxel in Heavily Pretreated Ovarian Cancer Patients
Current Medicinal Chemistry Resveratrol as a Chemopreventive Agent: A Promising Molecule for Fighting Cancer
Current Drug Targets Aspirin Use on Incidence and Mortality of Gastrointestinal Cancers: Current State of Epidemiological Evidence
Current Pharmaceutical Design Chemical Space of FLT3 Inhibitors as Potential Anti-AML Drugs
Recent Patents on Anti-Cancer Drug Discovery Mechanisms of Resistance to Imatinib in CML Patients: A Paradigm for the Advantages and Pitfalls of Molecularly Targeted Therapy
Current Cancer Drug Targets Advent and Maturation of Regenerative Medicine
Current Stem Cell Research & Therapy